Back to Authors

Dagradi, Federica

https://orcid.org/0000-0002-1090-3292

A5076644064 | I4210134201

Mayo Clinic

IRCCS Istituto Auxologico Italiano

Citations 13

SCN5A mutations in 442 neonates and children: genotype–phenotype correlation and identification of higher-risk subgroups

European Heart Journal | July 3, 2018 | Volume: 39 | Issue: 31 | Pages: 2879-2887

10.1093/eurheartj/ehy412 | PMID 30059973

Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study

Cardiovascular Research | February 17, 2015 | Volume: 106 | Issue: 3 | Pages: 520-529

10.1093/cvr/cvv042 | PMID 25691538

Characterization of SEMA3A -Encoded Semaphorin as a Naturally Occurring K v 4.3 Protein Inhibitor and its Contribution to Brugada Syndrome

Circulation Research | June 25, 2014 | Volume: 115 | Issue: 4 | Pages: 460-469

10.1161/circresaha.115.303657 | PMID 24963029

Rationale : Semaphorin 3A ( SEMA3A )-encoded semaphorin is a chemorepellent that disrupts neural patterning in the nervous and cardiac systems. In addition, SEMA3A has an amino acid motif that is analogous to hanatoxin, an inhibitor of voltage-gated K + channels. SEMA3A -knockout mice exhibit an abnormal ECG pattern and are prone to ventricular arrhythmias and sudden cardiac death. Objective : Our aim was to determine whether SEMA3A is a naturally occurring protein inhibitor of K v 4.3 (I to ) channels and its potential contribution to Brugada syndrome. Methods and Results : K v 4.3, Na v 1.5, Ca v 1.2, or K v 4.2 were coexpressed or perfused with SEMA3A in HEK293 cells, and electrophysiological properties were examined via whole-cell patch clamp technique. SEMA3A selectively altered K v 4.3 by significantly reducing peak current density without perturbing K v 4.3 cell surface protein expression. SEMA3A also reduced I to current density in cardiomyocytes derived from human-induced pluripotent stem cells. Disruption of a putative toxin binding domain on K v 4.3 was used to assess physical interactions between SEMA3A and K v 4.3. These findings in combination with coimmunoprecipitations of SEMA3A and K v 4.3 revealed a potential direct binding interaction between these proteins. Comprehensive mutational analysis of SEMA3A was performed on 198 unrelated SCN5A genotype–negative patients with Brugada syndrome, and 2 rare SEMA3A missense mutations were identified. The SEMA3A mutations disrupted SEMA3A’s ability to inhibit K v 4.3 channels, resulting in a significant gain of K v 4.3 current compared with wild-type SEMA3A. Conclusions : This study is the first to demonstrate SEMA3A as a naturally occurring protein that selectively inhibits K v 4.3 and SEMA3A as a possible Brugada syndrome susceptibility gene through a K v 4.3 gain-of-function mechanism.